AbbVie has pointed to a very strong launch trajectory for Elahere, with sales rocketing to $480 million last year, almost ...

Measles cases in the European region doubled to 127,350 in 2024, reaching the highest level in nearly three decades and ...

The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...

According to Prof Phil Banfield, chair of the BMA council, it had become clear that the centre "no longer has a grip on the ...

One of the key open questions in cell and gene therapy is which will win out: autologous cell therapies, where the patient’s ...

Jane Chung, president and chief operating officer at Sutro, is replacing Bill Newell as chief executive as the company starts ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...

It takes around seven years to develop a new drug and bring it to market. With the advent of GenAI, businesses in the life ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...

The European Commission has proposed new legislation to safeguard the supply of critical medicines in the EU by boosting ...

President Donald Trump has withdrawn his nomination of Dave Weldon to lead the CDC, just hours before he was due to appear in ...

The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...